Daito Pharmaceutical Co., Ltd. Logo

Daito Pharmaceutical Co., Ltd.

Manufactures APIs, generic drugs, and health foods; provides contract manufacturing services.

4577 | T

Overview

Corporate Details

ISIN(s):
JP3486150000
LEI:
Country:
Japan
Address:
富山市八日町326番地
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Daito Pharmaceutical Co., Ltd. is a pharmaceutical company engaged in the research, development, manufacturing, and sale of pharmaceutical products. The company operates an integrated business model that covers the entire production process, from active pharmaceutical ingredients (APIs) to finished formulation products, including powders, granules, and tablets. Its portfolio consists of generic drugs (both prescription and over-the-counter), health foods, and quasi-drugs. In addition to its own products, Daito serves other pharmaceutical firms by supplying APIs for generic products and offering contract manufacturing (CMO) services. The company emphasizes a stable supply of high-quality products managed by a strict quality assurance system.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-13 07:52
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 25.5 KB
2025-08-27 08:15
Registration Form
確認書
Japanese 8.3 KB
2025-08-27 08:13
Annual Report
有価証券報告書-第83期(2024/06/01-2025/05/31)
Japanese 1.4 MB
2025-06-12 09:16
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 23.3 KB
2025-05-13 09:22
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 26.0 KB
2025-04-11 08:53
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 25.3 KB
2025-03-12 08:08
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 24.7 KB
2025-02-13 08:56
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 24.2 KB
2025-01-17 09:04
M&A Activity
臨時報告書
Japanese 34.3 KB
2025-01-10 08:56
Report Publication Announcement
確認書
Japanese 8.3 KB
2025-01-10 08:54
Interim Report
半期報告書-第83期(2024/06/01-2025/05/31)
Japanese 194.9 KB
2024-09-02 08:00
Post-Annual General Meeting Information
臨時報告書
Japanese 21.8 KB
2024-08-30 07:43
Registration Form
確認書
Japanese 8.2 KB
2024-08-30 07:41
Governance Information
内部統制報告書-第82期(2023/06/01-2024/05/31)
Japanese 22.1 KB
2024-08-30 07:38
Annual Report
有価証券報告書-第82期(2023/06/01-2024/05/31)
Japanese 1.3 MB

Automate Your Workflow. Get a real-time feed of all Daito Pharmaceutical Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Daito Pharmaceutical Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Daito Pharmaceutical Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Chemical Works of Gedeon Richter Plc Logo
Develops and manufactures drugs for women's health, CNS, and cardiovascular diseases.
Hungary
RICHT
Chemomab Therapeutics Ltd. Logo
Develops antibody drugs neutralizing CCL24 for severe fibro-inflammatory diseases.
United States of America
CMMB
CHINA PHARMA HOLDINGS, INC. Logo
Develops, manufactures, and sells prescription, OTC, and nutritional products for human use.
United States of America
CPHI
China SXT Pharmaceuticals, Inc. Logo
Researches, produces, and sells advanced Traditional Chinese Medicine (TCM) herbal products.
United States of America
SXTC
ChoA Pharmaceutical Co., LTD. Logo
Global manufacturer of OTC medicines and health supplements distributed through pharmacies.
South Korea
034940
CHUGAI PHARMACEUTICAL CO., LTD. Logo
An R&D pharma leader in Japan creating innovative drugs via antibody engineering technology.
Japan
4519
Cinclus Pharma Holding AB Logo
Clinical-stage pharma developing a next-gen P-CAB drug for severe GERD patients.
Sweden
CINPHA
Cingulate Inc. Logo
Developing once-daily, precision timed-release drugs for ADHD and anxiety.
United States of America
CING
Circio Holding ASA Logo
Developing circular RNA vector tech and immunotherapies for gene and cell therapies.
Norway
CRNA
CITIUS ONCOLOGY, INC. Logo
Commercializing LYMPHIR™, an FDA-approved targeted therapy for cutaneous T-cell lymphoma.
United States of America
CTOR

Talk to a Data Expert

Have a question? We'll get back to you promptly.